Research programme: monoclonal antibody therapeutics - CheckmAb
Latest Information Update: 14 Mar 2025
At a glance
- Originator CheckmAb
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Regulatory T-lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Mar 2025 Preclinical trials in Solid tumours in Italy (Parenteral), before March 2025
- 14 Mar 2025 Pharmacodynamics data from preclinical trial in Solid tumours released by Checkmab, before March 2025 (Checkmab website, March 2025)